Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease

Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yenamandra, Avani, Marjoncu, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Prescriber's Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810265/
https://www.ncbi.nlm.nih.gov/pubmed/33489427
http://dx.doi.org/10.6004/jadpro.2020.11.8.7
_version_ 1783637279373262848
author Yenamandra, Avani
Marjoncu, Dennis
author_facet Yenamandra, Avani
Marjoncu, Dennis
author_sort Yenamandra, Avani
collection PubMed
description Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older.
format Online
Article
Text
id pubmed-7810265
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-78102652021-01-23 Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease Yenamandra, Avani Marjoncu, Dennis J Adv Pract Oncol Prescriber's Corner Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older. Harborside Press LLC 2020 2020-11-01 /pmc/articles/PMC7810265/ /pubmed/33489427 http://dx.doi.org/10.6004/jadpro.2020.11.8.7 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Prescriber's Corner
Yenamandra, Avani
Marjoncu, Dennis
Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title_full Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title_fullStr Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title_full_unstemmed Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title_short Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
title_sort voxelotor: a hemoglobin s polymerization inhibitor for the treatment of sickle cell disease
topic Prescriber's Corner
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810265/
https://www.ncbi.nlm.nih.gov/pubmed/33489427
http://dx.doi.org/10.6004/jadpro.2020.11.8.7
work_keys_str_mv AT yenamandraavani voxelotorahemoglobinspolymerizationinhibitorforthetreatmentofsicklecelldisease
AT marjoncudennis voxelotorahemoglobinspolymerizationinhibitorforthetreatmentofsicklecelldisease

Ejemplares similares